Full-Time

Quality Assurance Coordinator

Cooper Companies

Cooper Companies

201-500 employees

Global medical devices and vision care

No salary listed

Sugar Land, TX, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Data Analysis

Get referred to Cooper Companies

See people who can refer or advise you

Requirements
  • Entry level quality professional; responsible for quality oversight of processes in Quality Management Systems, operations, review and/or release of products.
  • Strong written and verbal communication skills to foster cross-functional collaboration and partnerships.
  • Ability to acquire in depth knowledge of Quality Assurance and the importance of quality processes in patient care.
  • Must be able to work with cross functional teams and maintain integrity and continuous improvement mindset.
Responsibilities
  • Support Quality Systems under the direction of Quality Assurance Manager.
  • Follows written instructions in the routine review of laboratory records in accordance with site standard operating procedures, good documentation practices (GDP) and Quality Management Systems (QMS).
  • Maintain understanding of company standards, guidelines and QMS processes to support and help stakeholders with applicable instructions.
  • Perform control processes such as data entry counting, verification, issuance, receipt, and reconciliation of any discrepancies.
  • Perform data entry, data analysis, tracking, trending, creating graphs and reports as required for each Quality Management System modules monitoring timeliness and effectiveness.
  • Maintenance of Record Management, electronic Document Management System and update document binders, indexes, and documentation therein.
  • Communicate and collaborates with appropriate staff and Project Teams regarding Document revision staff. Aid in writing, revising procedures and formatting.
  • Perform compliance review on executed records for completeness of all required testing and documents for various processes.
  • Supports Minor Non-conformance investigations which may contain basic root cause analysis.
  • Uses existing procedures to solve routine or standard problems.
  • Basic conceptual knowledge and practices associated with Document Review.
  • Recognizes errors in records and resolves them in a timely manner.
  • Supports basic improvement projects.
  • Work cooperatively in a team environment to maintain cross functional, and cross site processes and procedural consistency for quality systems records.
  • Perform other Quality Assurance Duties as required.

Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.

Company Size

201-500

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

1958

Get referred to Cooper Companies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 9, 2026 guidance raised fiscal 2026 revenue to $4.229-$4.252 billion.
  • MyDay MiSight and clariti launches are expanding across Japan, EMEA, and APAC.
  • Free cash flow reached $273 million in Q3 fiscal 2026, supporting $1 billion buybacks.

What critics are saying

  • CooperSurgical's 2023 embryo-media recall triggered $271.6 million charges and 140-plus lawsuits.
  • CooperVision's U.S. channel inventory reductions flattened Q3 revenue and cut fiscal guidance.
  • Persistent IVF safety concerns can permanently damage CooperSurgical's franchise with fertility clinics.

What makes Cooper Companies unique

  • CooperVision's MyDay daily silicone hydrogel portfolio drives premium contact-lens share globally.
  • CooperSurgical spans fertility, genomics, and women’s health, covering the reproductive-care workflow.
  • Cooper sells in 130-plus countries, pairing global distribution with vertically integrated manufacturing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Performance Bonus

Health Insurance

401(k) Retirement Plan

Life Insurance

Wellness Program

Professional Development Budget

Company News

Yahoo Finance
Sep 9th, 2026
CooperCompanies reports $1.08B Q1 revenue, up 7.9% year-on-year, beating estimates by 2.7%

CooperCompanies reported first-quarter revenues of $1.08 billion, up 7.9% year-on-year and exceeding analyst expectations by 2.7%. The medical device manufacturer, which focuses on vision care contact lenses and women's health products, also beat earnings per share estimates. The result came as the medical devices and supplies sector reported a strong quarter overall. Five tracked companies in the diversified category beat consensus revenue estimates by 2.9% on average, though next quarter's guidance came in 2.2% below expectations. Despite delivering the weakest full-year guidance update in the group, CooperCompanies' shares have risen 9% since reporting. The stock currently trades at $67.62.

Yahoo Finance
Sep 9th, 2026
Cooper Companies reports $271.8M record quarterly free cash flow, retains CooperSurgical after strategic review

Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.

Yahoo Finance
Sep 9th, 2026
CooperCompanies misses Q2 revenue estimates by 2.9%, cuts full-year guidance, stock drops 16.8%

CooperCompanies reported second-quarter revenue of $1.07 billion, missing analyst estimates of $1.10 billion. The medical device company's sales were flat year-on-year, whilst its operating margin improved to 20.8% from 16.6% in the same quarter last year. The company lowered its full-year revenue guidance to $4.24 billion at the midpoint, down from $4.30 billion, representing a 1.5% decrease. Adjusted earnings per share guidance was also reduced to $4.53 at the midpoint, a 1.9% decrease. Despite beating analyst expectations with adjusted EPS of $1.15 versus estimates of $1.12, the company's shares fell 16.8% following the announcement. CEO Al White cited reduced US channel inventory at CooperVision as weighing on results. CooperCompanies develops medical devices for vision care and women's health.

Associated Press
Sep 9th, 2026
CooperCompanies Q3 revenue up 1% to $1.07B, nets $307M UK tax benefit

CooperCompanies reported third quarter fiscal 2026 revenue of $1.066 billion, up 1% year-over-year. The medical device company posted GAAP diluted earnings per share of $2.24, compared with $0.49 in the prior year quarter, primarily driven by a $307.2 million discrete tax benefit from a favourable UK tax examination completion. Non-GAAP diluted EPS reached $1.15, up 4% from last year. Free cash flow increased 66% to $273.0 million. The company repurchased $339.1 million of common stock during the quarter. CooperVision revenue was flat at $717.0 million, whilst CooperSurgical revenue rose 2% to $349.2 million, with 6% fertility growth. The company cited reduced US channel inventory at CooperVision impacting results. CooperCompanies updated its fiscal 2026 guidance, projecting total revenue of $4.229-$4.252 billion and non-GAAP diluted EPS of $4.51-$4.55.

Yahoo Finance
Jun 8th, 2026
Cooper Companies' international revenue rises 7.9% to $1.08B, with EMEA contributing $287M

The Cooper Companies reported total revenue of $1.08 billion for the quarter ending April 2026, up 7.9% year over year. International markets contributed significantly to this performance, with EMEA generating $289.7 million (26.8% of total revenue) and Asia Pacific adding $130.6 million (12.1%). EMEA revenue exceeded Wall Street expectations by 5.18%, whilst Asia Pacific fell marginally short by 0.17%. The surgical and contact lens products maker's EMEA performance represented growth from $248.6 million in the year-ago quarter, though Asia Pacific revenue declined from $138.6 million over the same period. For the current fiscal quarter, analysts project total revenue of $1.12 billion, with EMEA expected to contribute $305.46 million and Asia Pacific $143.73 million.